Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
Vertex Pharmaceuticals Inc VRTX
News
Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain
Vertex Names Jonathan Poole Finance Chief as Crinetics Buy Closes
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
Vertex to Participate in Upcoming September Investor Conferences
Vertex Shares Rise as Rival Sionna's Cystic-Fibrosis Trial Fails to Meet Endpoint
Vertex Pharmaceuticals Bumps Up Fiscal Year Outlook on Growth of Cystic Fibrosis Drugs
Vertex Reports Second Quarter 2026 Financial Results
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
Vertex Pharmaceuticals Currently Down Seven Consecutive Days, on Pace for Longest Losing Streak Since August 2021 — Data Talk
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy
Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
Cantor Sees 'Clear Strategic Rationale' Behind Vertex's Buy of Crinetics — Market Talk
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion
Vertex to Acquire Crinetics Pharmaceuticals
Vertex Pharmaceuticals Gets FDA OK for Sickle Cell Disease Treatment in Young Children
Vertex Pharmaceuticals Says New Pain Management Drug Is Under Review at Health Canada
Vertex Pharmaceuticals Ends Study of Cystic Fibrosis Drug Over Tolerability Issues
Vertex Pharmaceuticals Posts Higher 1Q Profit
United States